Comparative Pharmacology
Head-to-head clinical analysis: DESFLURANE versus HALOTHANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESFLURANE versus HALOTHANE.
DESFLURANE vs HALOTHANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.
Halothane is a volatile halogenated hydrocarbon anesthetic that acts as a positive allosteric modulator of GABA-A receptors and glycine receptors, and inhibits NMDA and nicotinic acetylcholine receptors, leading to neuronal hyperpolarization and general anesthesia.
Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).
Induction: 0.5-3% in oxygen or oxygen-nitrous oxide mixture, titrated to effect; Maintenance: 0.5-2% in oxygen or oxygen-nitrous oxide mixture.
MODERATE Risk
MODERATE Risk
Clinical Note
moderateHalothane + Torasemide
"The risk or severity of adverse effects can be increased when Halothane is combined with Torasemide."
Clinical Note
moderateDesflurane + Torasemide
"The risk or severity of adverse effects can be increased when Desflurane is combined with Torasemide."
Clinical Note
moderateHalothane + Etacrynic acid
"The risk or severity of adverse effects can be increased when Halothane is combined with Etacrynic acid."
Clinical Note
moderateDesflurane + Etacrynic acid
Terminal elimination half-life is 3.5–4.5 minutes (context-sensitive half-life after prolonged anesthesia can be longer due to distribution, but true elimination is rapid due to low blood/gas partition coefficient).
Terminal elimination half-life approximately 5-10 hours post-anesthesia, with a slower terminal phase (up to 3 days) due to redistribution from fat stores. Clinically, washout is rapid initially but prolonged exposure in obese patients may lead to detectable levels for days.
Primarily eliminated via exhalation; minimal hepatic metabolism (<0.02%). Renal excretion of metabolites negligible. >99% excreted unchanged by lungs.
Primarily eliminated via pulmonary excretion (60-80% unchanged); approximately 20% metabolized in liver via CYP2E1, with metabolites excreted renally (trifluoroacetic acid, chloride, bromide). Only about 0.5% excreted unchanged in urine. Fecal excretion negligible.
Category C
Category C
General Anesthetic
General Anesthetic
"The risk or severity of adverse effects can be increased when Desflurane is combined with Etacrynic acid."